• T M Uskach, A A Safiullina, O V Sapel'nikov, V A Amanatova, O A Nikolaeva, I R Grishin, B M Nazarov, and S N Tereshchenko.
• National Medical Research Center for Cardiology.
• Terapevt Arkh. 2020 Oct 14; 92 (9): 8-14.

Aimto evaluate the effectiveness of cardiac contractility modulation (MSS) in patients with chronic heart failure (CHF) and atrial fibrillation (AF).Materials And MethodsThe following studies were performed in 40 patients with CHF and AF before implantation of the MSS device and after 2 and 6 months of follow-up: 12-channel ECG, transthoracic EchoCG, 6-minute walk test, determination of the level of Pro-natriuretic N-terminal peptide (NT-proBNP), daily ECG monitoring, and a questionnaire based on the Minnesota quality of life questionnaire for patients with CHF (MHFLQ). All patients received long-term optimal drug therapy for CHF before surgery.ResultsThe results obtained indicate a statistically significant positive effect of the use of MSS in patients with CHF and AF on LV FV, the functional class of CHF, and levels of NT-proBNP regardless of the etiology of CHF.ConclusionThe use of MSS may be promising for the treatment of heart failure in patients with CHF and AF.

12 keywords...

hide…